Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR5 | P35346 | 20/20 | 0.56 |
| ▸ | SSTR1 | P30872 | 2/20 | 0.53 |
| ▸ | HRH1 | P35367 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2417158 | 0.91 | SSTR5 (0.48) | SSTR5SSTR1HRH1KCNH2 | |
| SCHEMBL2425348 | 0.91 | SSTR5 (0.51) | SSTR5SSTR1HRH1KCNH2 | |
| SCHEMBL2419803 | 0.91 | SSTR5 (0.59) | SSTR5SSTR1KCNH2 | |
| SCHEMBL2412354 | 0.90 | SSTR5 (0.58) | SSTR5SSTR1HRH1KCNH2 | |
| SCHEMBL2421802 | 0.88 | KDM4E (0.54) | SSTR5SSTR1HRH1 | |
| SCHEMBL2418994 | 0.87 | MCHR1 (0.46) | SSTR5SSTR1HRH1 | |
| SCHEMBL2422696 | 0.87 | SSTR5 (0.49) | SSTR5SSTR1HRH1 | |
| SCHEMBL2419035 | 0.87 | SSTR5 (0.58) | SSTR5SSTR1HRH1 | |
| SCHEMBL2418375 | 0.87 | SSTR5 (0.56) | SSTR5SSTR1HRH1KCNH2 | |
| SCHEMBL2419573 | 0.86 | SSTR5 (0.54) | SSTR5SSTR1HRH1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8026255-B2 | Substituted piperidines as somatostatin receptor subtype 5 (SSTR5) antagonists | HOFFMAN-LA ROCHE INC. (US) | 2011-09-27 | — | — | US | claimed |
| US-20100222350-A1 | PHENYL, PYRIDINE, QUINOLINE, ISOQUINOLINE, NAPHTHYRIDINE AND PYRAZINE DERIVATIVES | BINGGELI ALFRED | 2010-09-02 | — | — | US | claimed |
| CN-101506165-A | Phenyl, pyridine and quinoline derivatives | HOFFMANN LA ROCHE (CH) | 2009-08-12 | — | — | CN | claimed |
| US-20080045544-A1 | Phenyl, Pyridine, Quinoline, Isoquinoline, Naphthyridine and Pyrazine Derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2008-02-21 | — | — | US | claimed |
| US-8026255-B2 | Substituted piperidines as somatostatin receptor subtype 5 (SSTR5) antagonists | HOFFMAN-LA ROCHE INC. (US) | 2011-09-27 | — | — | US | disclosed |
| US-20100222350-A1 | PHENYL, PYRIDINE, QUINOLINE, ISOQUINOLINE, NAPHTHYRIDINE AND PYRAZINE DERIVATIVES | BINGGELI ALFRED | 2010-09-02 | — | — | US | disclosed |
| US-7754744-B2 | Substituted piperidinamines as somatostatin receptor subtype 5 (SSTR5) antagonists | HOFFMANN-LA ROCHE INC. (US) | 2010-07-13 | — | — | US | disclosed |
| CN-101506165-A | Phenyl, pyridine and quinoline derivatives | HOFFMANN LA ROCHE (CH) | 2009-08-12 | — | — | CN | disclosed |
| US-20080045544-A1 | Phenyl, Pyridine, Quinoline, Isoquinoline, Naphthyridine and Pyrazine Derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222350-A1 | PHENYL, PYRIDINE, QUINOLINE, ISOQUINOLINE, NAPHTHYRIDINE AND PYRAZINE DERIVATIVES | SSTR5, SSTR3, SSTR1 | SSTR5 1/4885SSTR1 3/4885HRH1 156/4885 |
| US-20080045544-A1 | Phenyl, Pyridine, Quinoline, Isoquinoline, Naphthyridine and Pyrazine Derivatives | SSTR5, SSTR3, SSTR1 | SSTR5 1/4885SSTR1 3/4885HRH1 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.